Zacks Company Profile for Syros Pharmaceuticals, Inc. (SYRS : NSDQ) |
|
|
|
Company Description |
Syros Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on treatments for cancer and immune-mediated diseases as well as building a pipeline of gene control medicines. The company's product pipeline includes SY-1425, a selective RARa agonist for genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia and relapsed high-risk myelodysplastic syndrome and SY-1365, a selective CDK7 inhibitor for acute leukemia which is in preclinical stage. Syros Pharmaceuticals, Inc. is based in Cambridge, Massachusetts.
Number of Employees: 118 |
|
|
|
Price / Volume Information |
Yesterday's Closing Price: $3.70 |
Daily Weekly Monthly
 |
20 Day Moving Average: 87,956 shares |
Shares Outstanding: 20.60 (millions) |
Market Capitalization: $76.20 (millions) |
Beta: 1.67 |
52 Week High: $11.50 |
52 Week Low: $2.42 |
Short Interest Ratio: |
|
% Price Change |
% Price Change Relative to S&P 500 |
4 Week |
18.59% |
14.10% |
12 Week |
2.49% |
-4.86% |
Year To Date |
3.06% |
-6.25% |
|
|
|
|
|
Address & Contact Information |
Street Address |
Phone / Fax |
Email Address |
Web URL |
35 Cambridge Park Drive 4th Floor - CAMBRIDGE,MA 02140 USA |
ph: 617-744-1340 fax: - |
khunady@syros.com |
http://www.syros.com |
|
|
|
General Corporate Information |
Officers
Nancy Simonian - President; Chief Executive Officer and Director
Peter Wirth - Chairman
Jason Haas - Chief Financial Officer
Srinivas Akkaraju - Director
Mark J. Alles - Director
|
|
Peer Information
Syros Pharmaceuticals, Inc. (CORR.)
Syros Pharmaceuticals, Inc. (RSPI)
Syros Pharmaceuticals, Inc. (CGXP)
Syros Pharmaceuticals, Inc. (BGEN)
Syros Pharmaceuticals, Inc. (GTBP)
Syros Pharmaceuticals, Inc. (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 87184Q206
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/23
Next Expected EPS Date: 08/08/23
|
|
Share - Related Items
Shares Outstanding: 20.60
Most Recent Split Date: 9.00 (0.10:1)
Beta: 1.67
Market Capitalization: $76.20 (millions)
|
|
|
|
|
|
EPS Information |
Dividend Information |
Analyst Coverage: No |
Dividend Yield: 0.00% |
Current Fiscal Quarter EPS Consensus Estimate: $-1.10 |
Indicated Annual Dividend: $0.00 |
Current Fiscal Year EPS Consensus Estimate: $-4.18 |
Payout Ratio: |
Number of Estimates in the Fiscal Year Consensus: 4.00 |
Change In Payout Ratio: |
Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
Next EPS Report Date: 08/08/23 |
|
|
|
|